Progress in aromatase research and identification of key future directions

Journal of Steroid Biochemistry and Molecular Biology

Volumn 118, Issue 4-5, 2010, Pages 311-315

  Dunbier, Anita K ^a   Hong, Yanyan ^b   Masri, Selma ^b   Brown, Kristy A ^c   Sabnis, Gauri J ^d   Palomares, Melanie R ^b  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^c HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

^d UNIVERSITY OF MARYLAND   (United States)

Author keywords

Aromatase; Meeting report

Indexed keywords

ANASTROZOLE; AROMATASE; AROMATASE INHIBITOR; EXEMESTANE; LETROZOLE; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

BREAST CANCER; CANCER PREVENTION; CANCER RESEARCH; CANCER RESISTANCE; CLINICAL PRACTICE; CONFERENCE PAPER; CRYSTAL STRUCTURE; DRUG STRUCTURE; DRUG TARGETING; ENZYME REGULATION; ENZYME STRUCTURE; HUMAN; MOLECULARLY TARGETED THERAPY; NONHUMAN; PROTEIN EXPRESSION; PROTEIN TARGETING; TARGET ORGAN; TRANSLATIONAL RESEARCH; ARTICLE; CHEMISTRY; GENETICS; METABOLISM; NEOPLASM;

ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE; AROMATASE INHIBITORS; HUMANS; NEOPLASMS; TRANSLATIONAL RESEARCH;

EID: 77950354358     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2009.09.005     Document Type: Conference Paper

References (55)

1. N. Kagawa, H. Hori, M.R. Waterman, S. Yoshioka, Characterization of stable human aromatase expressed in E. coli, Steroids 69 (4) (2004) 235-243.
2. N. Yoshida, Y. Osawa, Purification of human placental aromatase cytochrome P-450 with monoclonal antibody and its characterization, Biochemistry 30 (12) (1991) 3003-3010.
3. S. Chen, S. Masri, Y. Hong, X. Wang, S. Phung, Y.C. Yuan, et al., New experimental models for aromatase inhibitor resistance, J. Steroid Biochem. Mol. Biol. 106 (1-5) (2007) 8-15.
4. A.D. Favia, A. Cavalli, M. Masetti, A. Carotti, M. Recanatini, Three-dimensional model of the human aromatase enzyme and density functional parameterization of the iron-containing protoporphyrin IX for a molecular dynamics study of heme-cysteinato cytochromes, Proteins 62 (4) (2006) 1074-1087.
5. S. Graham-Lorence, B. Amarneh, R.E. White, J.A. Peterson, E.R. Simpson, A threedimensional model of aromatase cytochrome P450, Protein Sci. 4 (6) (1995) 1065-1080.
6. Y. Hong, B. Yu, M. Sherman, Y.C. Yuan, D. Zhou, S. Chen, Molecular basis for the aromatization reaction and exemestane-mediated irreversible inhibition of human aromatase, Mol. Endocrinol. 21 (2) (2007) 401-414.
7. D. Ghosh, X-ray structure of human placental aromatase: molecular basis for androgen specificity and estrogen synthesis. Presented at IX International Aromatase Conference, Shanghai, China, 13-16th October (2008).
8. D. Ghosh, J. Griswold, M. Erman, W. Pangborn, Structural basis for androgen specificity and oestrogen synthesis in human aromatase, Nature 457 (7226) (2009) 219-223.
9. Y. Hong, H. Li, Y.C. Yuan, S. Chen, Molecular and structural characterization of aromatase. Presented at IX International Aromatase Conference, Shanghai, China, 13-16th October (2008).
10. P. Hadji, Menopausal symptoms and adjuvant therapy-associated adverse events, Endocr. Relat. Cancer 15 (1) (2008) 73-90.
11. W.A. Ricke, S.J. McPherson, J.J. Bianco, G.R. Cunha, Y. Wang, G.P. Risbridger, Prostatic hormonal carcinogenesis is mediated by in situ estrogen production and estrogen receptor alpha signaling, Faseb J. 22 (5) (2008) 1512-1520.
12. E.R. Simpson, M.E. Jones, Of mice and men: the many guises of estrogens, Ernst Schering Found. Symp. Proc. 1 (2006) 45-67.
13. S.E. Bulun, E.R. Simpson, Aromatase expression in women's cancers, Adv. Exp. Med. Biol. 630 (2008) 112-132.
14. M. Sofi, M.J. Young, T. Papamakarios, E.R. Simpson, C.D. Clyne, Role of CREbinding protein (CREB) in aromatase expression in breast adipose, Breast Cancer Res. Treat. 79 (3) (2003) 399-407.
15. M.D. Michael, L.F. Michael, E.R. Simpson, A CRE-like sequence that binds CREB and contributes to cAMP-dependent regulation of the proximal promoter of the human aromatase P450 (CYP19) gene, Mol. Cell. Endocrinol. 134 (2) (1997) 147-156.
16. S. Chen, D. Zhou, C. Yang, T. Okubo, Y. Kinoshita, B. Yu, et al., Modulation of aromatase expression in human breast tissue, J. Steroid Biochem. Mol. Biol. 79 (1-5) (2001) 35-40.
17. C.D. Clyne, C.J. Speed, J. Zhou, E.R. Simpson, Liver receptor homologue-1 (LRH- 1) regulates expression of aromatase in preadipocytes, J. Biol. Chem. 277 (23) (2002) 20591-20597.
18. J. Zhou, T. Suzuki, A. Kovacic, R. Saito, Y. Miki, T. Ishida, et al., Interactions between prostaglandin E(2), liver receptor homologue-1, and aromatase in breast cancer, Cancer Res. 65 (2) (2005) 657-663.
19. R. Safi, A. Kovacic, S. Gaillard, Y. Murata, E.R. Simpson, D.P. McDonnell, et al., Coactivation of liver receptor homologue-1 by peroxisome proliferatoractivated receptor gamma coactivator-1alpha on aromatase promoter II and its inhibition by activated retinoid X receptor suggest a novel target for breastspecific antiestrogen therapy, Cancer Res. 65 (24) (2005) 11762-11770.
20. C.D. Clyne, A. Chand, K. Herridge, S. To, K. Knower, N. Flemming, et al., Regulation of aromatase expression by nuclear receptors, in: Proceedings of the IX International Aromatase Conference, Shanghai, China, 2008.
21. S. Ghosh, Y. Lu, A. Katz, Y. Hu, R. Li, Tumor suppressor BRCA1 inhibits a breast cancer-associated promoter of the aromatase gene (CYP19) in human adipose stromal cells, Am. J. Physiol. Endocrinol. Metab. 292 (1) (2007) E246-E252.
22. S. Deb, J. Zhou, S.A. Amin, A.G. Imir, M.B. Yilmaz, Z. Lin, et al., A novel role of sodium butyrate in the regulation of cancer-associated aromatase promoters I.3 and II by disrupting a transcriptional complex in breast adipose fibroblasts, J. Biol. Chem. 281 (5) (2006) 2585-2597.
23. R. Rajhans, H.B. Nair, S.S. Nair, V. Cortez, K. Ikuko, N.B. Kirma, et al., Modulation of in situ estrogen synthesis by proline-, glutamic acid-, and leucine-rich protein-1: potential estrogen receptor autocrine signaling loop in breast cancer cells, Mol. Endocrinol. 22 (3) (2008) 649-664.
24. K.A. Brown, K.J. McInnes, E.R. Simpson, Sex, fat and breast cancer. Presented at IX International Aromatase Conference Shanghai, China, 13-16th October (2008).
25. R.W. Brueggemeier, B. Su, M.V. Darby, Y. Sugimoto, Selective regulation of aromatase expression for drug discovery. Presented at IX International Aromatase Conference Shanghai, China, 13-16th October (2008).
26. B. Su, E.S. Diaz-Cruz, S. Landini, R.W. Brueggemeier, Suppression of aromatase in human breast cells by a cyclooxygenase-2 inhibitor and its analog involves multiple mechanisms independent of cyclooxygenase-2 inhibition, Steroids 73 (1) (2008) 104-111.
27. M.H. Cohen, J.R. Johnson, N. Li, G. Chen, R. Pazdur, Approval summary: letrozole in the treatment of postmenopausal women with advanced breast cancer, Clin. Cancer Res. 8 (3) (2002) 665-669.
28. M.H. Cohen, S. Hirschfeld, S.FlammHonig, A. Ibrahim, J.R. Johnson, J.J. O'Leary, et al., Drug approval summaries: arsenic trioxide, tamoxifen citrate, anastrazole, paclitaxel, bexarotene, Oncologist 6 (1) (2001) 4-11.
29. W. Yue, D. Zhou, S. Chen, A. Brodie, A new nude mouse model for postmenopausal breast cancer using MCF-7 cells transfected with the human aromatase gene, Cancer Res. 54 (19) (1994) 5092-5095.
30. B.J. Long, D. Jelovac, V. Handratta, A. Thiantanawat, N. MacPherson, J. Ragaz, et al., Therapeutic strategies using the aromatase inhibitor letrozole and tamoxifen in a breast cancer model, J. Natl. Cancer Inst. 96 (6) (2004) 456-465.
31. D. Jelovac, G. Sabnis, B.J. Long, L. Macedo, O.G. Goloubeva, A.M. Brodie, Activation of mitogen-activated protein kinase in xenografts and cells during prolonged treatment with aromatase inhibitor letrozole, Cancer Res. 65 (12) (2005) 5380-5389.
32. S. Masri, S. Phung, X. Wang, X. Wu, Y.C. Yuan, L. Wagman, et al., Genome-wide analysis of aromatase inhibitor-resistant, tamoxifen-resistant, and long-term estrogen-deprived cells reveals a role for estrogen receptor, Cancer Res. 68 (12) (2008) 4910-4918.
33. W.R. Miller, A. Larionov, L. Renshaw, T.J. Anderson, S. White, G. Hampton, et al., Aromatase inhibitors-gene discovery, J. Steroid Biochem. Mol. Biol. 106 (1-5) (2007) 130-142.
34. A. Brodie, G. Sabnis, Aromatase resistance mechanisms in in vivo model systems. Presented at IX International Aromatase Conference, Shanghai, China, 13-16th October (2008).
35. S. Masri, S. Phung, X. Wang, X. Wu, Y.C. Yuan, S. Chen, Molecular characterization of aromatase inhibitor-resistant, tamoxifen-resistant and LTEDaro cell lines. Presented at IX International Aromatase Conference, Shanghai, China, 13-16th October (2008).
36. R.J. Santen, The IGF-1-R and EGF-R and development of resistance to aromatase inhibitors. Presented at IX International Aromatase Conference, Shanghai, China, 13-16th October (2008).
37. A. Dunbier, H. Anderson, Z. Ghazoui, B. Haynes, I. Smith, M. Dowsett, Molecular determinants of response to aromatase inhibitor treatment. Presented at IX International Aromatase Conference, Shanghai, China, 13-16th October (2008).
38. W.R. Miller, Clinical, pathological, proliferative and molecular responses associated with neoadjuvant AI treatment. Presented at IX International Aromatase Conference, Shanghai, China, 13-16th October (2008).
39. R.J. Santen, R.X. Song, Z. Zhang, R. Kumar, M.H. Jeng, S. Masamura, et al., Adaptive hypersensitivity to estrogen: mechanisms and clinical relevance to aromatase inhibitor therapy in breast cancer treatment, J. Steroid Biochem. Mol. Biol. 95 (1-5) (2005) 155-165.
40. G.J. Sabnis, D. Jelovac, B. Long, A. Brodie, The role of growth factor receptor pathways in human breast cancer cells adapted to long-term estrogen deprivation, Cancer Res. 65 (9) (2005) 3903-3910.
41. C.-Y. Shen, Unique feature of breast cancer in Asia-a demographic analysis. Presented at IX International Aromatase Conference, Shanghai, China, 13-16th October (2008).
42. Z.-M. Shao, Unique challenges in treating premenopausal women in Asia: a regional perspective. Presented at IX International Aromatase Conference, Shanghai, China, 13-16th October (2008).
43. L.W.C. Chow, A new era of hormonal therapy in breast cancer treatment. Presented at IX International Aromatase Conference, Shanghai, China, 13-16th October (2008).
44. C.F. Chiu, H.C. Wang, C.H. Wang, C.L. Wang, C.C. Lin, C.Y. Shen, et al., A new single nucleotide polymorphism in XRCC4 gene is associated with breast cancer susceptibility in Taiwanese patients, Anticancer Res. 28 (1A) (2008) 267-270.
45. C.S. Huang, S.H. Kuo, H.C. Lien, S.Y. Yang, S.L. You, C.Y. Shen, et al., The CYP19 TTTA repeat polymorphism is related to the prognosis of premenopausal stage I-II and operable stage III breast cancers, Oncologist 13 (7) (2008) 751-760.
46. K.M. Giacomini, C.M. Brett, R.B. Altman, N.L. Benowitz, M.E. Dolan, D.A. Flockhart, et al., The pharmacogenetics research network: from SNP discovery to clinical drug response, Clin. Pharmacol. Ther. 81 (3) (2007) 328-345.
47. J. Ragaz, P. Pisani, Z. Ying, Changing breast cancer mortality trends in the Western world compared the East: lives gained, lives lost. Presented at IX International Aromatase Conference, Shanghai, China, 13-16th October (2008).
48. P. Porter, Westernizing women's risks? Breast cancer in lower-income countries, N. Engl. J. Med. 358 (3) (2008) 213-216.
49. G.P. Risbridger, S.J. MacPherson, S.J. Ellem, Too much, too little or the right kind: the importance of estrogen in the prostate. Presented at IX International Aromatase Conference, Shanghai, China, 13-16th October (2008).
50. H. Sasano, R. Miki, T. Shibuya, T. Suzuki, Intratumoral production of estrogen in Ductal Carcinoma In Situ (DCIS) of human breast with comparison to invasion carcinoma. Presented at IX International Aromatase Conference, Shanghai, China, 13-16th October (2008).
51. H. Sasano, C. Vachon, K. Ghosh, K. Brandt, R.J. Santen, D. Watson et al., Aromatase expression and breast density. Presented at IX International Aromatase Conference, Shanghai, China, 13-16th October (2008).
52. L. Morales, S. Pans, K. Verschueren, B. Van Calster, R. Paridaens, R. Westhovens, et al., Prospective study to assess short-term intra-articular and tenosynovial changes in the aromatase inhibitor-associated arthralgia syndrome, J. Clin. Oncol. 26 (19) (2008) 3147-3152.
53. S.A. Jaramillo, D. Felton, L. Andrews, L. Desiderio, R.K. Hallarn, S.D. Jackson, et al., Enrollment in a brain magnetic resonance study: results from the Women's Health Initiative Memory Study Magnetic Resonance Imaging Study (WHIMSMRI), Acad. Radiol. 14 (5) (2007) 603-612.
54. S.M. Resnick, L.H. Coker, P.M. Maki, S.R. Rapp, M.A. Espeland, S.A. Shumaker, The Women's Health Initiative Study of Cognitive Aging (WHISCA): a randomized clinical trial of the effects of hormone therapy on age-associated cognitive decline, Clin. Trials 1 (5) (2004) 440-450.
55. S.R. Rapp, M.A. Espeland, S.A. Shumaker, V.W. Henderson, R.L. Brunner, J.E. Manson, et al., Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial, JAMA 289 (20) (2003) 2663-2672.